KemPharm to Report Third Quarter 2021 Results
04 November 2021 - 12:22AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs,
today announced that the Company will host a conference call and
live audio webcast on Wednesday, November 10, 2021, at 4:30
p.m. ET, to discuss its corporate and financial results for the
third quarter 2021.
Conference Call
Information:
Telephone Access: |
To access the conference call telephonically, interested
participants and investors will be required to register via the
following online form:
http://www.directeventreg.com/registration/event/6718737 |
|
|
|
Once registered, all individuals will be provided with participant
dial-in numbers, a passcode and a registrant ID, which can then be
used to access the conference call. |
|
|
|
Participants may register at any time. It is recommended that the
registration process be completed at least 15 minutes prior to the
start of the call. |
|
|
Webcast Access: |
The live audio webcast with slide presentation will be accessible
via the Investor Relations section of KemPharm’s
website, http://investors.kempharm.com/. An archive of the
webcast and presentation will be available for 90 days beginning at
approximately 5:30 p.m. ET, on November 10, 2021. |
|
|
Investors may submit questions to KemPharm prior
to the Third Quarter 2021 Results conference call by e-mail to
mmcenroe@tiberend.com. Please use the e-mail subject heading
“KemPharm Third Quarter 2021 Question” to ensure that the
information is received. KemPharm’s management will then respond to
select questions during the conference call.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). KemPharm’s lead
clinical development candidate for the treatment of SUD, KP879, is
based on its prodrug of d-methylphenidate, known as
serdexmethylphenidate (SDX). In addition, KemPharm has received FDA
approval for AZSTARYS®, a new once-daily treatment for ADHD in
patents age six years and older, and for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
KemPharm Contacts:
Jason Rando / Maureen McEnroeTiberend Strategic
Advisors, Inc.(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2024 to May 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From May 2023 to May 2024